{
    "nct_id": "NCT04511130",
    "official_title": "A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation",
    "inclusion_criteria": "Inclusion Criteria\n\n1. First allogeneic HSCT, in ≤ CR2, and MRD negative prior to transplant (including matched sibling, MUD with at least 6 of 8 HLA markers, or haploidentical with at least 5 of 10 HLA markers) as:\n\n   * Adjuvant therapy for AML (Group 1) at 85-130 days post-HSCT defined as patients with CRMRD; or\n   * Treatment for refractory/relapsed AML (first relapse post-HSCT) when disease occurs after transplant (Group 2) defined as\n\n     * First relapse (MRD+ or frank relapse) post-HSCT\n     * Patients in Arm 1B (SOC) who experience first relapse (MRD+ or frank relapse) post HSCT\n   * Safety Lead-in defined as patients who fit all the criteria for Group 2 only\n2. Are ≥18 years of age\n3. Karnofsky/ Lansky score of ≥60\n4. Life expectancy ≥12 weeks\n5. Adequate blood, liver, and renal function\n\n   * Blood: Hemoglobin ≥7.0 g/dL (can be transfused)\n   * Liver: Bilirubin ≤2X upper limit of normal; aspartate aminotransferase ≤3X upper limit of normal\n   * Renal: Serum creatinine ≤2X upper limit of normal or measured or calculated creatinine clearance ≥45mL/min\n\n7. Patients are allowed to be on experimental conditioning regimens prior to transplant if no planned maintenance therapy post-transplant.\n\n8. In Group 2, patients may receive bridging therapy at the investigators' discretion in situations where MT-401 is not ready for administration or the treating physician believes the patient would benefit\n\nExclusion Criteria\n\n1. Clinically significant or severely symptomatic intercurrent infection\n2. Pregnant or lactating\n3. For Group 1, anti-neoplastic therapy after HSCT and prior to or during dosing of MT-401\n4. For Group 2, concomitant anti-neoplastic therapy during or after dosing of MT-401\n5. Evidence of acute or chronic GVHD ≥Grade 2 (exception: acute or chronic Grade 2 GVHD of skin allowed if stable) within one week prior to receiving MT-401\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}